Provided by Tiger Trade Technology Pte. Ltd.

Kodiak Sciences Inc.

98.46
+3.663.86%
Post-market: 98.650.1900+0.19%19:59 EDT
Volume:3.79M
Turnover:376.81M
Market Cap:6.16B
PE:-23.68
High:104.00
Open:95.41
Low:93.95
Close:94.80
52wk High:104.00
52wk Low:10.94
Shares:62.58M
Float Shares:39.01M
Volume Ratio:0.36
T/O Rate:9.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1571
EPS(LYR):-4.3220
ROE:-368.37%
ROA:-60.45%
PB:100.85
PE(LYR):-22.78

Loading ...

Movement Alert|Kodiak Sciences Inc. Surges 146.43% in Regular Trading, Two Eye Drug Candidates Meet Primary Endpoints in Phase 3 Trial

Market Focus
·
Sep 28

Kodiak Sciences Shares Hit 52-Week High After Positive Phase 3 Trial

Dow Jones
·
Sep 28

Kodiak Sciences up Nearly 154%, on Pace for Record Percent Increase

Dow Jones
·
Sep 28

Kodiak Sciences rises 136.7%

TIPRANKS
·
Sep 28

Kodiak Sciences Shares up 123% After Co's Eye-Disease Drugs Meet Trial Goals

THOMSON REUTERS
·
Sep 28

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Oil Prices Rise

MT Newswires Live
·
Sep 28

Sector Update: Healthcare

MT Newswires Live
·
Sep 28

Nvidia, Meta, SpaceX, Kodiak Sciences, MongoDB, Boeing, and More Stocks That Explain Today's Market

Dow Jones
·
Sep 28

The Stock Market Faces a Triple Threat but it Can Emerge Victorious

Dow Jones
·
Sep 28

Top Premarket Gainers

MT Newswires Live
·
Sep 28

Kodiak Sciences Rises After Eye-Disease Drugs Meet Trial Goals

Reuters
·
Sep 28

Kodiak Sciences Shares up 32% Premarket After Zenkuda and Tabirafusp-Ted Meet Primary Endpoints in Daybreak Trial in Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
Sep 28

Kodiak Sciences Says Zenkuda Meets Primary Endpoint in Phase 3 Daybreak Wet AMD Trial

Reuters
·
Sep 28

Zenkuda and Tabirafusp-Ted Meet Primary Endpoints in Pivotal Daybreak Trial in Wamd, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-Week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.

THOMSON REUTERS
·
Sep 28

Kodiak Sciences - Zenkuda Bla Planned for Q4 2026 to Include Five Positive Phase 3 Studies

THOMSON REUTERS
·
Sep 28

Kodiak Sciences Inc. - Zenkuda and Tabirafusp-Ted Demonstrated Safety Consistent with Established Safety Profile of Aflibercept

THOMSON REUTERS
·
Sep 28

Stocks to Watch: Kodiak Sciences, Circle Internet Group

Dow Jones
·
Sep 26

Kodiak Sciences Shares Surge Ahead of Phase 3 Readout

Dow Jones
·
Sep 26

Kodiak Sciences Upcoming Data Could Support Upside, UBS Says

MT Newswires Live
·
Sep 25

Kodiak Sciences (KOD) Initiated with a Hold at Goldman Sachs

TIPRANKS
·
Sep 24